Last reviewed · How we verify
Dexamethasone 0.1% and tobramycin 0.3%
At a glance
| Generic name | Dexamethasone 0.1% and tobramycin 0.3% |
|---|---|
| Also known as | TobraDex |
| Sponsor | Bausch & Lomb Incorporated |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery (PHASE4)
- Effect of Bromfenac on Pain Related to Pterygium Surgery (PHASE4)
- Bevacizumab Injection for Recurrent Pterygium
- A Bioequivalence Study to Compare the Pharmacokinetics (PK) Of Marketed Product TobraDex® To An Experimental Ophthalmic Sterile Ointment Containing Tobramycin And Dexamethasone In Aqueous Humor In Patients Undergoing Indicated Cataract Surgery (PHASE3)
- Ketorolac Plus Tobramycin/Dexamethasone Versus Tobramycin/Dexamethasone After Uneventful Phacoemulsification Surgery (NA)
- A Bioequivalence Study of Tobradex AF (PHASE3)
- Zylet vs TobraDex in Blepharokeratoconjunctivitis (PHASE4)
- Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: